Hematopoietic Stem Cell Transplantation Market Analysis

Hematopoietic Stem Cell Transplantation Market Analysis

>

To get key market trends

  Download Free Sample

Based on therapy type, the hematopoietic stem cell transplantation market is divided into allogeneic transplant therapy and autologous transplant therapy. The autologous transplant therapy segment held the largest market share of 57.6% in 2022. Autologous transplantation eliminates the need to find a compatible donor, which can be challenging in allogeneic transplantation. This reduces the time and resources required for donor search and facilitates a quicker transplantation process. Moreover, autologous HSCT allows for the use of higher doses of chemotherapy or radiation, which can be more effective in killing cancer cells or suppressing the immune system in autoimmune diseases. The subsequent infusion of the patient's own stem cells helps restore the bone marrow and immune system.
 

Based on indication type, the hematopoietic stem cell transplantation market is divided into lymphoproliferative disorders, leukemia, non-malignant disorders, and other indications. The leukemia segment is further subdivided into acute myeloid leukemia, acute lymphatic leukemia, myelodysplastic syndrome, and other leukemia. The leukemia segment held the largest market share of 72% in 2022. Leukemia is one of the most common cancers worldwide affecting significant number of people. The high incidence of leukemia drives the demand for effective treatments, including HSCT, especially in cases where other therapies have been less successful. The lymphoproliferative disorders segment is further subdivided into non-hodgkin lymphoma, hodgkin lymphoma, plasma cell disorders, and other lymphoproliferative disorders.
 

Based on application type, the hematopoietic stem cell transplantation market is divided into bone marrow stem cell transplant, peripheral blood stem cell transplant, and cord blood transplant. Bone marrow stem cell transplantation offers the potential for a cure in certain haematological disorders, especially in cases where standard treatments have been ineffective, or disease relapse has occurred. Its ability to provide long-term disease-free survival makes it a critical treatment option for eligible patients

The bone marrow stem cell transplantation is the treatment of choice for several haematological conditions, including leukemia, lymphoma, multiple myeloma, and aplastic anemia.

Based on end-user, the hematopoietic stem cell transplantation market is classified into hospitals, specialty clinics, and other end-users. The hospitals segment held dominant market share of around 52.5% in 2022 and is expected to grow at a significant pace of 9.1% by 2032. Hospitals are equipped with comprehensive healthcare facilities, including specialized units for bone marrow transplantation. These facilities enable hospitals to offer a full range of services required for the preparation, transplantation, and post-transplant care of HSCT patients.
 

North America hematopoietic stem cell transplantation marketis expected to reach USD 2.2 billion in 2032 with a CAGR of 9.1% by 2032. North America boasts a well-developed and advanced healthcare infrastructure, including specialized transplant centers and comprehensive cancer centers. These facilities provide access to state-of-the-art technology, expertise, and resources necessary for successful HSCT procedures.
 

Moreover, North America has a relatively high incidence of haematological disorders, such as leukemia, lymphoma, and multiple myeloma. According to American Cancer Society, it is estimated that there will be 59,610 new cases of leukemia in 2023.